To date, as many as 14,000 patients in the United States per year are diagnosed with glioblastoma, the most common and most malignant primary brain tumor. Glioblastomas are characterized by their ability to evade treatment on many fronts, thus a novel approach to curative therapies is imperative. A population of cells with stem cell-like properties are found within glioblastoma tumors and drive their initiation and progression. Identification of extracellular markers on these tumor stem cells is thus paramount. The cell surface glycoproteins CD133 and CD147 were examined as potential markers of cancer stem cells found in glioblastoma. Here we found evidence which shows that formation of neurospheres with U87MG glioblastoma cells may be driven by increased expression of CD147, correlated with increased CD133 expression. These findings suggest that relative levels of CD147 expression may be used as a determinant to target cancer stem cells in glioblastoma.
","abstract_html":"<p>To date, as many as 14,000 patients in the United States per year are diagnosed with glioblastoma, the most common and most malignant primary brain tumor. Glioblastomas are characterized by their ability to evade treatment on many fronts, thus a novel approach to curative therapies is imperative. A population of cells with stem cell-like properties are found within glioblastoma tumors and drive their initiation and progression. Identification of extracellular markers on these tumor stem cells is thus paramount. The cell surface glycoproteins CD133 and CD147 were examined as potential markers of cancer stem cells found in glioblastoma. Here we found evidence which shows that formation of neurospheres with U87MG glioblastoma cells may be driven by increased expression of CD147, correlated with increased CD133 expression. These findings suggest that relative levels of CD147 expression may be used as a determinant to target cancer stem cells in glioblastoma.</p>","abstract_has_math":false,"creators":["McMahon, Christopher"],"institution":null,"degree_name":"Master of Science","degree_level":"Thesis","degree_discipline":"Biology","degree_department":null,"school":null,"contributors":["Dr. Robert Winn"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2016,"date_issued":"2016-05-01T07:00:00Z","date_published":"2016-05-01T07:00:00Z","updated_at":"2026-07-24T03:23:34Z","subjects":["CD133","CD147","Cancer Stem Cells","Medical Microbiology","Medicine and Health Sciences"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://commons.nmu.edu/theses/86","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Dr. Robert Winn"]},{"key":"dc:creator","label":"Author","values":["McMahon, Christopher"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2016-04-08T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Biology"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["CD133","CD147","Cancer Stem Cells","Medical Microbiology","Medicine and Health Sciences"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://commons.nmu.edu/theses/86"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["To date, as many as 14,000 patients in the United States per year are diagnosed with glioblastoma, the most common and most malignant primary brain tumor. Glioblastomas are characterized by their ability to evade treatment on many fronts, thus a novel approach to curative therapies is imperative. A population of cells with stem cell-like properties are found within glioblastoma tumors and drive their initiation and progression. Identification of extracellular markers on these tumor stem cells is thus paramount. The cell surface glycoproteins CD133 and CD147 were examined as potential markers of cancer stem cells found in glioblastoma. Here we found evidence which shows that formation of neurospheres with U87MG glioblastoma cells may be driven by increased expression of CD147, correlated with increased CD133 expression. These findings suggest that relative levels of CD147 expression may be used as a determinant to target cancer stem cells in glioblastoma.
"]},{"key":"dc:title","label":"Title","values":["EXAMINATION OF CD133 AND CD147 AS CANCER STEM CELL MARKERS"]}]}],"canonical_facts":{"dc:contributor":["Dr. Robert Winn"],"dc:creator":["McMahon, Christopher"],"dc:date.available":["2016-04-08T07:00:00Z"],"dc:description.abstract":["To date, as many as 14,000 patients in the United States per year are diagnosed with glioblastoma, the most common and most malignant primary brain tumor. Glioblastomas are characterized by their ability to evade treatment on many fronts, thus a novel approach to curative therapies is imperative. A population of cells with stem cell-like properties are found within glioblastoma tumors and drive their initiation and progression. Identification of extracellular markers on these tumor stem cells is thus paramount. The cell surface glycoproteins CD133 and CD147 were examined as potential markers of cancer stem cells found in glioblastoma. Here we found evidence which shows that formation of neurospheres with U87MG glioblastoma cells may be driven by increased expression of CD147, correlated with increased CD133 expression. These findings suggest that relative levels of CD147 expression may be used as a determinant to target cancer stem cells in glioblastoma.
"],"dc:identifier":["https://commons.nmu.edu/theses/86"],"dc:subject":["CD133","CD147","Cancer Stem Cells","Medical Microbiology","Medicine and Health Sciences"],"dc:title":["EXAMINATION OF CD133 AND CD147 AS CANCER STEM CELL MARKERS"],"thesis:degree_discipline":["Biology"],"thesis:degree_level":["Thesis"],"thesis:degree_name":["Master of Science"]},"updated_at":"2026-07-24T03:23:34Z"}